SCHEMBL10144892

SCHEMBL10144892

COc1ccc2oc(/C=C/c3ccc([N+](=O)[O-])cc3)cc(=O)c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.71
MAOB P27338 2/20 0.71
MAPT P10636 4/20 0.65
KDM4E B2RXH2 3/20 0.65
ALDH1A1 P00352 4/20 0.65
HPGD P15428 3/20 0.65
PTGS2 P35354 3/20 0.54
PTGS1 P23219 1/20 0.54
TLR9 Q9NR96 1/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MEN1 O00255 1/20 0.51
GAA P10253 1/20 0.51
KMT2A Q03164 1/20 0.51
STS P08842 1/20 0.51
APP P05067 3/20 0.49
HNF4A P41235 2/20 0.48
NFE2L2 Q16236 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4991870 1.00 MAOA (0.71) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL10144893 0.83 MAOA (0.78) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL4992744 0.83 MAOA (0.78) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL4987022 0.82 GABRP (0.62) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL10144977 0.82 KDM4E (0.47) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL10144898 0.81 MAOA (0.74) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL4987371 0.81 MAOA (0.74) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL10144902 0.81 MAOA (0.74) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL4983225 0.81 MAOA (0.74) MAOAMAOBMAPTKDM4EALDH1A1
SCHEMBL9976010 0.81 MAPT (0.70) MAOAMAOBMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed
EP-1815872-A1 COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS Nagasaki University (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases APP, APBA1, FABP7 MAOA 2873/4885MAOB 2191/4885MAPT 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.